Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $114

Benzinga · 2d ago
Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $107 to $114.